{"id":59061,"date":"2024-02-28T05:40:05","date_gmt":"2024-02-28T05:40:05","guid":{"rendered":"https:\/\/medsname.com\/seroquit\/"},"modified":"2026-04-30T10:24:04","modified_gmt":"2026-04-30T10:24:04","slug":"seroquit","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/seroquit\/","title":{"rendered":"Seroquit"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f<\/h3>\n

Seroquit (Quetiapine 25 \/ 50 \/ 100 \/ 200 \/ 300 mg, immediate-release) is an atypical antipsychotic for schizophrenia, bipolar mania, bipolar depression, MDD adjunct, and GAD adjunct. Strongly sedating and metabolically heavy \u2014 but uniquely effective for bipolar depression. Often misused as a “sleeping pill” \u2014 discouraged because of metabolic burden.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Seroquit at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a> \u2014 20pracovn\u00edchdenn\u00ed lh\u016fta pro doru\u010den\u00ed, nebo v\u00e1m z\u00e1silku zdarma p\u0159epo\u0161leme \u2014 a oprav\u0148uje v\u00e1s k \u00fa\u010dasti v na\u0161em v\u011brnostn\u00edm programu<\/a>. Dod\u00e1v\u00e1me do v\u011bt\u0161iny zem\u00ed po cel\u00e9m sv\u011bt\u011b.<\/p>\n

What Seroquit is and how it works<\/h2>\n

Seroquit is a quetiapine immediate-release tablet supplied by Cipla. Available strengths: 25 \/ 50 \/ 100 \/ 200 \/ 300 mg<\/strong>. Quetiapine has loose D2 binding (rapid dissociation explains low EPS), strong 5-HT2A antagonism, very strong H1 antihistamine action (sedation, weight gain), \u03b11-adrenergic antagonism (orthostasis), and \u03b12 antagonism. Its active metabolite, norquetiapine, has noradrenaline transporter inhibition \u2014 the basis for the antidepressant effect in bipolar depression.<\/p>\n

IR is dosed BID or TID. The strong sedation peaks 1\u20132 hours after each dose.<\/p>\n

Indikace a d\u00e1vkov\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Indikace<\/th>\nPo\u010d\u00e1te\u010dn\u00ed d\u00e1vka<\/th>\nC\u00edlov\u00e1 d\u00e1vka<\/th>\nMaxim\u00e1ln\u00ed d\u00e1vka<\/th>\n<\/tr>\n<\/thead>\n
Schizophrenia (IR)<\/td>\n50 mg p\u0159ed span\u00edm<\/td>\n400\u2013800 mg\/day<\/td>\n800 mg<\/td>\n<\/tr>\n
Bipolar mania<\/td>\n50 mg BID (IR) or 300 mg HS (SR)<\/td>\n400\u2013800 mg\/day<\/td>\n800 mg<\/td>\n<\/tr>\n
Bipolar depression<\/td>\n50 mg p\u0159ed span\u00edm<\/td>\n300 mg HS<\/td>\n600 mg<\/td>\n<\/tr>\n
MDD adjunct (SR)<\/td>\n50 mg p\u0159ed span\u00edm<\/td>\n150\u2013300 mg HS<\/td>\n300 mg<\/td>\n<\/tr>\n
GAD adjunct (off-label)<\/td>\n50 mg p\u0159ed span\u00edm<\/td>\n50\u2013150 mg HS<\/td>\n\u2014<\/td>\n<\/tr>\n
Older adults<\/td>\n25 mg p\u0159ed span\u00edm<\/td>\n50\u2013200 mg\/day<\/td>\nby tolerability<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

D\u016fle\u017eit\u00e9 bezpe\u010dnostn\u00ed aspekty<\/h2>\n
\nFDA black-box \u2014 dementia-related psychosis<\/strong><\/p>\n

All atypical antipsychotics carry an FDA black-box warning for increased mortality (mostly cardiovascular and infectious) when used to treat behavioural disturbance in older adults with dementia. Atypicals are not approved for dementia-related psychosis or agitation<\/strong>. Use in this population is off-label, last-resort, time-limited, and requires explicit risk-benefit conversation.<\/p>\n<\/div>\n

\nHeavy metabolic burden<\/strong><\/p>\n

Weight gain, insulin resistance, dyslipidaemia \u2014 second only to olanzapine and clozapine among atypicals. Mandatory monitoring at baseline, 12 weeks, then 6-monthly: weight, fasting glucose \/ HbA1c, fasting lipids, BP. Counsel about diet\/exercise from initiation.<\/p>\n<\/div>\n

\nOrthostatic hypotension<\/strong><\/p>\n

\u03b11 antagonism produces orthostatic hypotension, particularly in older adults and at initiation. Titrate slowly. Check sitting and standing BP at follow-up.<\/p>\n<\/div>\n

\n“Off-label sleep aid” \u2014 discouraged<\/strong><\/p>\n

Low-dose quetiapine (25\u201350 mg HS) is widely used off-label as a hypnotic. The metabolic burden is the same regardless of indication \u2014 patients on quetiapine for sleep gain weight and develop insulin resistance just as much as patients on quetiapine for psychosis. Dedicated hypnotics (Z-drugs, low-dose doxepin, melatonin agonists, behavioural sleep therapy) are usually safer choices for primary insomnia.<\/p>\n<\/div>\n

\nSuicidality (under-25, MDD adjunct use)<\/strong><\/p>\n

When used as an antidepressant adjunct, the under-25 suicidality warning applies.<\/p>\n<\/div>\n

\u010cast\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/h2>\n